Working… Menu

Minocycline in Primary Sclerosing Cholangitis (PSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00630942
Recruitment Status : Completed
First Posted : March 7, 2008
Last Update Posted : December 7, 2010
Information provided by:
Mayo Clinic

Brief Summary:
The purpose of the study is to see how safe and effective minocycline is in the treatment of Primary Sclerosing Cholangitis (PSC).

Condition or disease Intervention/treatment Phase
Primary Sclerosing Cholangitis Drug: Minocycline Phase 1

Detailed Description:
The purpose of the study is to determine the safety profile of minocycline in patients with PSC and to compare the effects of minocycline on the baseline values of the following parameters: symptoms of pruritus and fatigue, liver biochemistries, Mayo Risk Score, the development of clinical progression and complications of liver disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)
Study Start Date : February 2003
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Arm Intervention/treatment
Experimental: Single Arm, active treatment Drug: Minocycline
Minocycline 100 mg capsules twice a day before breakfast and before dinner.

Primary Outcome Measures :
  1. To evaluate the safety and estimate the efficacy at the maximally tolerated dose, 100 mg BID, in 30 patients with PSC. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Both genders
  • Females of childbearing age must have negative pregnancy test within 48 hours of participation and agreement to practice contraception for the duration of the study.
  • Age 18 years old and < than 75 years old.
  • History of chronic cholestatic disease of at least 6 months duration.
  • Serum alkaline phosphatase level at least 1.5 times the upper limit of normal.
  • Cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction, beading, or narrowing consistent with PSC.
  • Liver biopsy consistent with the diagnosis of PSC.
  • Patient's informed consent for study participation.

Exclusion Criteria:

  • Treatment with tetracyclines, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, pirfenidone, nicotine, tacrolimus, silymarin, vitamin E or prednisone in the preceding three months.
  • Findings highly suggestive of hepatobiliary disease of other etiology complicating PSC.
  • Anticipated need for liver transplantation in one year determined by the Mayo model with an estimate of <75% one year survival without transplantation.
  • Recurrent variceal bleeding, presence of ascites, or encephalopathy.
  • Active drug or alcohol use.
  • Pregnancy.
  • Breast-feeding.
  • Serum creatinine over 1.5 mg/dl.
  • Prior history of allergic reactions to antibiotics belonging to the tetracycline family.
  • Any condition that, in the opinion of the investigator, would interfere with the patient's ability to complete the study safely or successfully.
  • Patients with active inflammatory bowel disease (IBD) requiring specific treatment in the preceding three months, except for maintenance therapy with 5-ASA compounds, or those individuals who have been involved in a trial evaluating any experimental drug for the treatment of IBD in the preceding three months.
  • Recurrent ascending cholangitis requiring hospitalization in the past year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00630942

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Keith D. Lindor, M.D. Mayo Clinic
Layout table for additonal information
Responsible Party: Dr. Keith D. Lindor, M.D., Mayo Clinic Identifier: NCT00630942    
Other Study ID Numbers: 1559-02
First Posted: March 7, 2008    Key Record Dates
Last Update Posted: December 7, 2010
Last Verified: December 2010
Keywords provided by Mayo Clinic:
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Anti-Bacterial Agents
Anti-Infective Agents